Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

472 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE; I-Preserve Investigators. Zile MR, et al. Among authors: anand is. Circulation. 2010 Mar 30;121(12):1393-405. doi: 10.1161/CIRCULATIONAHA.109.909614. Epub 2010 Mar 15. Circulation. 2010. PMID: 20231531 Clinical Trial.
Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT).
Latini R, Masson S, Anand I, Judd D, Maggioni AP, Chiang YT, Bevilacqua M, Salio M, Cardano P, Dunselman PH, Holwerda NJ, Tognoni G, Cohn JN; Valsartan Heart Failure Trial Investigators. Latini R, et al. Circulation. 2002 Nov 5;106(19):2454-8. doi: 10.1161/01.cir.0000036747.68104.ac. Circulation. 2002. PMID: 12417542 Clinical Trial.
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
Cohn JN, Anand IS, Latini R, Masson S, Chiang YT, Glazer R; Valsartan Heart Failure Trial Investigators. Cohn JN, et al. Among authors: anand is. Circulation. 2003 Sep 16;108(11):1306-9. doi: 10.1161/01.CIR.0000091234.45664.62. Epub 2003 Aug 25. Circulation. 2003. PMID: 12939207 Clinical Trial.
Anemia and its relationship to clinical outcome in heart failure.
Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB. Anand I, et al. Circulation. 2004 Jul 13;110(2):149-54. doi: 10.1161/01.CIR.0000134279.79571.73. Epub 2004 Jun 21. Circulation. 2004. PMID: 15210591 Clinical Trial.
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial.
Anand I, McMurray J, Cohn JN, Konstam MA, Notter T, Quitzau K, Ruschitzka F, Lüscher TF; EARTH investigators. Anand I, et al. Lancet. 2004 Jul 24-30;364(9431):347-54. doi: 10.1016/S0140-6736(04)16723-8. Lancet. 2004. PMID: 15276394 Clinical Trial.
C-reactive protein in heart failure: prognostic value and the effect of valsartan.
Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN; Val-HeFT Investigators. Anand IS, et al. Circulation. 2005 Sep 6;112(10):1428-34. doi: 10.1161/CIRCULATIONAHA.104.508465. Epub 2005 Aug 29. Circulation. 2005. PMID: 16129801 Clinical Trial.
472 results